These previous results, together with our findings showing potent anti-CRPC activity of BCT, demonstrate the potential of repurposing a certain class of antimalarials for CRPC treatment and of HSP90 as a common therapeutic target for cancer and malaria. This evidence concerns the gene HSP90AA1 and malaria.